Article

Brain-Restricted mTOR Inhibition with Binary Pharmacology

2020-10-12

Abstract excerpt

On-target-off-tissue drug engagement is an important source of adverse effects that constrains the therapeutic window of drug candidates. In diseases of the central nervous system, drugs with brain-restricted pharmacology are highly desirable. Here we report a strategy to achieve inhibition of mTOR while sparing mTOR activity elsewhere through the use of a brain-permeable mTOR inhibitor RapaLink-1 and brain-imperm...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 48d8db3b-657a-5000-a2df-cdda96cda0b0
DOI: 10.1101/2020.10.12.336677

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Brain-Restricted mTOR Inhibition with Binary PharmacologyDOI 10.1101/2020.10.12.336677Read

Brain-Restricted mTOR Inhibition with Binary PharmacologySemantic proximity Read

Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1Semantic proximity Read

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.Semantic proximity Read

Identification of a Non-Gatekeeper Hot Spot for Drug-Resistant Mutations in mTOR Kinase.Semantic proximity Read

Drug discovery targeting the mTOR pathwaySemantic proximity Read

A New Challenging and Promising Era of Tyrosine Kinase InhibitorsSemantic proximity Read

Pharmacological PP2A reactivation overcomes multikinase inhibitor tolerance across brain tumor cell modelsSemantic proximity Read

Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.Semantic proximity Read

DYRK1A Kinase Inhibitors with Emphasis on CancerSemantic proximity Read

A High-Throughput In Vitro Drug Screen in a Genetically Engineered Mouse Model of Diffuse Intrinsic Pontine Glioma Identifies BMS-754807 as a Promising Therapeutic AgentSemantic proximity Read

Bi-steric mTORC1-selective Inhibitors activate 4EBP1 reversing MYC-induced tumorigenesis and synergize with immunotherapySemantic proximity Read

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumorsSemantic proximity Read